<DOC>
	<DOC>NCT02126358</DOC>
	<brief_summary>To evaluate the efficacy and safety of the fix-dose combination therapy with Gemigliptin 50mg and Rosuvastatin 20mg with type 2 diabetes and dyslipidemia</brief_summary>
	<brief_title>Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Type 2 Diabetes Mellitus with Dyslipidemia Adults who are at least 19 years old Patients with type 1 diabetes, diabetic ketoacidosis, diabetic coma and precoma Patients with gestational diabetes or secondary diabetes Patients with NYHA Class III, IV congestive heart failure or arrhythmias requiring treatment Patients with thyroid gland dysfunction deviating from the normal TSH range Patients with pituitary insufficiency or adrenal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>